Astex Pharmaceuticals, Inc.
ASTX, a pharmaceutical company dedicated to the discovery and
development of novel small molecule therapeutics, today announced that
clinical development of amuvatinib (MP-470), a multi-targeted tyrosine kinase
inhibitor that inhibits the mutant forms of c-Kit and PDGFR alpha and disrupts
DNA repair likely through suppression of homologous recombination protein
Rad51, has been discontinued.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in